| 摘要 |
Isolated nucleic acid (I) 8 fully defined nucleotide sequences (S1) given in the specification, a sequence at least 70% identical with (S1), or a sequence that hybridizes to (S1), or its complement, under stringent conditions. Independent claims are also included for the following: (a) isolated polypeptide (II), designated podocine that is either a fully defined 383 amino acid (aa) sequence (S2) given in the specification (human or rat), at least 70% identical with (S2), or encoded by a sequence that hybridizes to sequences of 1853 base pairs (bp) or 1652 bp, or their complements under stringent conditions; (b) isolated nucleic acid (Ia) that differs from the fully defined 1853 bp sequence by mutation, insertion or deletion; (c) isolated nucleic acid (Ib) that is a 1853 bp or 1652 bp sequence or encodes (II); (d) cloning and/or expression vector (III) containing (I), (Ia) or (Ib); (e) host cell (IV) transfected (III); (f) nucleic acid (Ic) comprising sequences 27 nucleotide sequences fully defined in the specification; (g) preparation of recombinant (II) by culturing (IV); (h) antibodies (Ab) directed against (II); In vitro method (M1) for diagnosing cortico-resistant nephrotic syndrome; and (i) pharmaceutical composition containing (II), or nucleic acid encoding it, plus a vehicle. |
